Zogenix
Treatments for central nervous system disorders and pain
Zogenix’s core strategy is to develop and commercialize differentiated central nervous system and pain therapeutics that can address significant unmet medical needs or overcome the limitations of existing products.
IPO in 2010 NASDAQ: ZGNX
Video
Roger Hawley, co-founder and CEO of Zogenix, talks about developing medications to address pain, including its product for migraines, DosePro.
Zogenix Team
ScaleVP Contact
Portfolio News
-
Seeking AlphaJanuary 3, 2012
-
ReutersAugust 17, 2011
